JNJ-68284528, CARVYKTI 3.2 × 10^6 – 1 × 10^8 cells dispersion for infusion
68284528MMY2012
Phase 2 small_molecule active
Quick answer
JNJ-68284528, CARVYKTI 3.2 × 10^6 – 1 × 10^8 cells dispersion for infusion for Newly Diagnosed Multiple Myeloma is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Newly Diagnosed Multiple Myeloma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active